Recent Run-Up Provides MAIA Biotechnology With Breathing Room [Seeking Alpha]
MAIA Biotechnology, Inc. (MAIA)
Company Research
Source: Seeking Alpha
The company presented data from its THIO-101 trial at the ASCO 2024 annual meeting, where the response rate was 38% in 3L NSCLC patients receiving 180 mg THIO. MAIA's share price run-up gives the company options, raising cash could allow it to initiate additional trials. MAIA Biotechnology, Inc. NYSE: MAIA ) is developing the telomere targeting agent, 6-thio-2'-deoxyguanosine ("THIO"), in a range of oncology conditions. I wrote about MAIA in July 2023, when I rated it a buy, as I expected, subsequent updates from the company's THIO-101 trial in non-small cell lung cancer ("NSCLC") to provide a rally. This article looks at where MAIA stands now following the recent update at the American Society of Clinical Oncology ("ASCO") 2024 annual meeting, and why I now rate the company a hold. The THIO-101 of THIO with Libtayo in 2L+ NSCLC MAIA's only trial underway is called THIO-101. THIO-101 looks at treating patients with second-line or beyond (2L+) NSCLC with THIO, followed by Libt
Show less
Read more
Impact Snapshot
Event Time:
MAIA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MAIA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MAIA alerts
High impacting MAIA Biotechnology, Inc. news events
Weekly update
A roundup of the hottest topics
MAIA
News
- MAIA Biotechnology's Telomere Targeting Functionality is Shown Viable by FDA’s Approval of a Telomerase Inhibitor Agent TherapyBusiness Wire
- MAIA Biotechnology Announces Year-to-Date Achievements and Highlights Recent Clinical Progress for Novel Anticancer Agent [Yahoo! Finance]Yahoo! Finance
- MAIA Biotechnology Announces Year-to-Date Achievements and Highlights Recent Clinical Progress for Novel Anticancer AgentBusiness Wire
- MAIA Biotechnology Reveals New Clinical Data Showing THIO's Strong Efficacy in Non-Small Cell Lung Cancer [Yahoo! Finance]Yahoo! Finance
- MAIA Biotechnology Reveals New Clinical Data Showing THIO’s Strong Efficacy in Non-Small Cell Lung CancerBusiness Wire
MAIA
Earnings
- 5/14/24 - Miss
MAIA
Sec Filings
- 6/6/24 - Form 8-K
- 6/4/24 - Form 8-K
- 6/3/24 - Form 8-K
- MAIA's page on the SEC website